Medical Device | April 01, 2024
MTD acquires Ypsomed's pen needle and BGM businesses
This acquisition enables MTD to open new, strategic markets
This acquisition enables MTD to open new, strategic markets
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Acute therapies continue to report strong growth compared to chronic ones.
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
